← Back to Screener
Bicara Therapeutics Inc. Common Stock (BCAX)
Price$23.47
Favorite Metrics
Price vs S&P 500 (26W)26.29%
Price vs S&P 500 (4W)20.93%
Market Capitalization$1.57B
All Metrics
Book Value / Share (Quarterly)$7.09
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.89
Price vs S&P 500 (YTD)38.52%
EPS (TTM)$-2.52
10-Day Avg Trading Volume0.57M
EPS Excl Extra (TTM)$-2.52
EPS (Annual)$-2.52
ROI (Annual)-34.36%
Cash / Share (Quarterly)$7.33
ROA (Last FY)-32.01%
EBITD / Share (TTM)$-2.84
Cash Flow / Share (Annual)$-1.89
P/B Ratio3.92x
P/B Ratio (Quarterly)2.30x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-349.41x
ROA (TTM)-30.87%
EPS Incl Extra (Annual)$-2.52
Current Ratio (Annual)14.58x
Quick Ratio (Quarterly)14.33x
3-Month Avg Trading Volume0.56M
52-Week Price Return104.17%
Revenue / Employee (TTM)$0
52-Week High$24.25
EPS Excl Extra (Annual)$-2.52
26-Week Price Return35.04%
Quick Ratio (Annual)14.33x
13-Week Price Return33.24%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.58x
Enterprise Value$1,475.182
Revenue / Employee (Annual)$0
Cash / Share (Annual)$7.33
3-Month Return Std Dev51.43%
Net Income / Employee (TTM)$-3
ROE (Last FY)-34.36%
EPS Basic Excl Extra (Annual)$-2.52
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.52
ROI (TTM)-32.49%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)69.07%
Year-to-Date Return42.66%
5-Day Price Return8.45%
EPS Normalized (Annual)$-2.52
Month-to-Date Return20.71%
EBITD / Share (Annual)$-2.84
EPS Basic Excl Extra (TTM)$-2.52
P/B Ratio (Annual)2.30x
Book Value / Share (Annual)$7.09
Price vs S&P 500 (13W)30.38%
Beta1.80x
Revenue / Share (TTM)$0.00
ROE (TTM)-32.49%
52-Week Low$7.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.06
4.11
4.05
4.10
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | — | — | — | — | $23.47 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies for solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed monoclonal antibody with a TGF-beta binding domain, targeting two clinically validated oncology pathways.